Table 1. Patient characteristics.
Characteristic | Median (range) |
---|---|
Age (in years) | 45 (25–55) |
Pre-chemotherapy AMH (in ng/mL) | 0.11 (0.01–8.63) |
N (%) | |
White race | 106 (85 %) |
Received bevacizumab | 94 (76 %) |
Used tamoxifen | 64 (52 %) |
12-month CRA | 102/124 (82 %) |
18-month CRA | 81/100 (81 %) |
CRA chemotherapy-related amenorrhea, AMH anti-mullerian hormone